In the field of cell and gene therapy (CGT), efficient and stable cell purification and elutriation are the core links to ensure efficacy and safety. To break through the efficiency bottleneck of traditional operations, Hemogen, an innovative enterprise under BGI Group focusing on the R & D of cell and gene therapy technologies, relying on its independent core technology platform and in collaboration with BGI Research, has successfully developed the fully enclosed automated cell purification and elutriation equipment, Celaxi - 23.
Core Advantages of Celaxi - 23: Precision and Efficiency in Parallel
Celaxi - 23 is equipped with an intelligent control system and precise separation technology to achieve precise control of cell purification and elutriation. Its core advantages are as follows:
High - purity guarantee: Through the centrifugation and dynamic washing modules, the purity of target cells is significantly improved, and invalid impurities are removed.
Optimized recovery rate: The gentle processing technology maximally preserves cell viability and ensures that each operation step does not damage cell functions.
Batch consistency: The automated process avoids errors in manual operations, helps to make experimental data stable and reliable, and accelerates the R & D process.
Integrated Solution to Accelerate Domestic and Overseas Layout
The automated and enclosed design of the Celaxi - 23 equipment reduces the high dependence on clean workshops, simplifies the cell preparation process, and reduces errors caused by manual operations. Combined with supporting consumables and customized kits, it forms a one - stop solution of "equipment + technology transfer + supply chain". This model significantly improves the technology transfer efficiency of cell and gene therapy products. Based on Celaxi - 23, Hemogen has developed a kit for its first pipeline product, HGI - 001 Injection (Hemo - cel), providing safe, efficient, and affordable gene therapy services for patients with hemoglobin diseases worldwide.
With its excellent performance, Celaxi - 23 has redefined the industry standard and is becoming an innovative tool to accelerate CGT R & D and production. So far, it has been successfully implemented in multiple benchmark scenarios: at the end of 2024, it was applied in the Haihe Laboratory of the Institute of Hematology, Chinese Academy of Medical Sciences; in April 2025, it passed the GMP workshop of Siriraj Hospital in Thailand and completed the process verification. Recently, after multiple rounds of testing and confirmation by the partner, the first commercialized Celaxi - 23 device was delivered and put into use, which will be used for the commercial preparation of the partner's CAR - T products and market expansion at home and abroad, marking the verification of the feasibility of the application scenarios of domestic equipment in the global market.
Empowering Industry Partners to Build a One - Stop Service
Celaxi - 23 is now open for cooperation with global CGT enterprises. We provide the following services and support for our partners:
Modular customization: Parameters can be flexibly adjusted according to customer needs to adapt to various cell types (such as CAR - T, NK, stem cells, etc.) and process flows.
Localized service: Provide full - range support from equipment commissioning to operation training to ensure rapid implementation and application.
Technology sharing: Continuously iterate and upgrade, and share the dividends of technological upgrades to help customers maintain industry competitiveness.
Channel collaboration: The cell and gene therapy products developed by customers based on the Celaxi - 23 equipment are expected to reach the global market through BGI and partner channels.
Exploring Emerging Markets and Establishing a Domestic Benchmark
Through the "equipment + technology transfer + supply chain" model, Celaxi - 23 will achieve rapid deployment in regions with rapidly growing cell therapy demand but weak technological foundation. The equipment has extremely strong compatibility and covers a wide range of cell types. While providing accessible treatment options for local patients, it also sets an example for domestic enterprises to expand overseas markets.
In the future, Hemogen will continue to take technology as the cornerstone and cooperation as the link, and work hand in hand with partners to promote the globalization process of domestic CGT products and equipment, achieve in - depth integration of technological innovation and clinical value, and help the cause of human health reach new heights.
Customers interested in testing the Celaxi - 23 equipment, please contact:
Dr. Dong, dongguoyi@genomics.cn, 18818795950
About Hemogen
Hemogen is committed to treating hemoglobin diseases and striving to achieve the grand goal of a world without "anemia".
Adhering to the vision and mission of "Genetic Technology Benefits Mankind", through close cooperation with the Shenzhen BGI Academy of Life Sciences and other BGI departments, and leveraging BGI Group's channel influence in the medical and health field, it has produced 17 patented achievements so far. Currently, the IND application for its first - in - sequence product, HGI - 001 Injection (for transfusion - dependent β - thalassemia), has been approved, and preparations for a registration clinical trial are underway.
It has independent R & D capabilities and a perfect quality management system, and owns two major gene modification technology platforms: lentiviral gene transfer and CRISPR/Cas gene editing. It has built a GMP workshop of about 1000 square meters, multiple product pipelines under research, and an operation team of more than 40 people, and continuously focuses on the R & D and application of gene therapy vectors and gene modification technologies.
Hemogen will continue to adhere to the mission of "Genetic Technology Benefits Mankind" and a world without "anemia", and make unremitting efforts to safeguard the health and well - being of patients with severe thalassemia!
Genetic Technology Benefits Mankind
Official website: thg66.com
Email: info@thg66.com
